EGFR G810S

CI-VAR-00001835Explore in graph →CIViC 1016 rs121913230

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
EGFR G810S	Erlotinib + GefitinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5824 EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independence to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR G810S	Multikinase Inhibitor AEE788	Predictive	D	Supports Sensitivity Response	2	submitted	EID5825 EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.